Holen Sie sich die Stockscreener-App
1.33
0.75%
-0.01
Handel nachbörslich:
1.33
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Clearmind Medicine (NASDAQ:CMND) Shares Down 12.3% – What’s Next? - Defense World
Clearmind Medicine Inc [CMND] Revenue clocked in at $0.00 million, down -51.60% YTD: What’s Next? - The DBT News
Clearmind advances trial for alcohol use disorder therapy - Investing.com
Clearmind advances trial for alcohol use disorder therapy By Investing.com - Investing.com Australia
Clearmind Medicine Inc (NASDAQ: CMND): Is Its Value Too High Compared To Others? - Stocks Register
Clearmind Medicine Inc Inc. (CMND) Price Performance: A Technical Analysis Perspective - The InvestChronicle
Examining CMND’s book value per share for the latest quarter - US Post News
Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical Site - Marketscreener.com
Rail Vision secures $20 million equity deal with Yorkville - Investing.com
SciSparc gains as Clearmind partnership yields 3 new international patent applications - MSN
Clearmind Medicine Completed Type A Meeting with the FDA - GlobeNewswire
SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - Marketscreener.com
Clearmind Medicine appoints new board member - Investing.com
Clearmind, SciSparc slide amid weight-loss study results - MSN
Could Psychedelics End Binge Drinking? A Breakthrough Patent Says Yes - MSN
Clearmind Medicine patents new addiction treatment - Investing.com India
SciSparc Unveils Breakthrough Ibogaine Therapy Patent - TipRanks
Clearmind Medicine Announces the Notice of an International Patent Application for Pioneering - The Bakersfield Californian
SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy - StockTitan
Contrasting Clearmind Medicine (NASDAQ:CMND) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Clearmind Medicine files patent for PTSD treatment compounds - Investing.com
Clearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD Treatment - Morningstar
SciSparc shares up on patents filed for psychedelic compounds with Clearmind - MSN
SciSparc and Clearmind Innovate Mental Health Treatment - TipRanks
Clearmind Medicine files patent for novel MDMA therapy - Investing.com
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment - Yahoo Finance UK
SciSparc-Clearmind Medicine Collaboration Leads to - GlobeNewswire
SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent ... - The Bakersfield Californian
A History of Outperforming Analyst Forecasts and Beating the Odds: Clearmind Medicine Inc (CMND) - SETE News
Financial Metrics Check: Clearmind Medicine Inc (CMND)’s Ratios for Trailing Twelve Months - The Dwinnex
Clearmind and SciSparc file patent for ketamine-based therapy - Investing.com
SciSparc and Clearmind Innovate in Mental Health Therapy - TipRanks
Clearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination Treatment - Morningstar
Clearmind Biomedical Announces FDA Clearance and First U.S. Surgery of the Neuroblade System for Minimally Invasive Neurosurgery - PR Newswire
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - Market Exclusive
CMND’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
Clearmind receives patent for drug to treat binge behavior - Green Market Report
Clearmind Medicine Inc (CMND) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Clearmind Medicine secures new US patent for binge behavior regulator - Investing.com India
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment - Yahoo Finance
Clearmind Medicine Inc (CMND) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Is CMND’s price to cash per share ratio a concern for investors? - US Post News
Financial Metrics Unveiled: Clearmind Medicine Inc (CMND)’s Key Ratios in the Spotlight - The Dwinnex
Thinking about buying stock in Brainstorm Cell Therapeutics, Cle - GuruFocus.com
Clearmind, Yissum Apply for International Patent for Psychedelics - MarketWatch
Clearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental Disorders - StockTitan
Clearmind Medicine (NASDAQ:CMND) Stock Price Down 0.8% - Defense World
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket - Benzinga
Clearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss Drug - EIN News
SciSparc and Clearmind report progress in obesity treatment - Investing.com
Move over Ozempic, psychedelics might help people lose weight - Green Market Report
SciSparc’s Collaboration with Clearmind Medicine Continues - GlobeNewswire
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):